Overview

Efficacy, Safety, and Pharmacokinetics of QAW039

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fluticasone
Indoleacetic Acids
Xhance